| Autor: |
Koyada, Irene, Arnaud, Bernas, Pop, Vlad, Danciu, Paul, Tristan, Bristena-Octavia, Burz, Claudia |
| Předmět: |
|
| Zdroj: |
Oncolog-Hematolog; 2023, Issue 64, p37-37, 1/3p |
| Abstrakt: |
Introduction. There is a growing awareness regarding gender influences on the response of cancer to immunotherapy that is reflected by an increasing number of studies in many cases of tumors, including melanoma. A new revolution was marked by immunotherapy in this setting, but neither predictive factors were identified in response, nor selection criteria for targeted therapy of immunotherapy. Materials and method. A retrospective study was initiated with the hypothesis of comparing the impact of gender for response in cancer patients diagnosed with metastatic melanoma. For the inclusion, the patients were selected independent of BRAF status, treated with the combination checkpoint inhibitor drugs PD-1 inhibitor/ CTLA-4 inhibitor: nivolumab/ipilimumab. For each patient, at the inclusion, the performance status was assessed, along with the neutrophils/lymphocytes ratio, thrombocytes/neutrophils ratio, and the value of LDH. Every patient was evaluated after four cycles of double immunotherapy and then every three months during the maintenance treatment. Statistical analyses will be performed to evaluate if there exists a statistical gender difference in response to double immunotherapy. Conclusions. The limited number of patients is not sufficient to validate the hypothesis, and more studies must be conducted on a larger cohort of patients to affirm the predictive value of the clinical and biological markers. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
